Brain and Central Nervous System Tumors Clinical Trial
Official title:
Phase II Trial of Velcade (Bortezomib) in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-diagnosed Glioblastoma Multiforme
Verified date | May 2019 |
Source | Jonsson Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,
such as temozolomide, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. Radiation therapy uses high-energy
x-rays to kill tumor cells. Giving bortezomib together with temozolomide and radiation
therapy may kill more tumor cells and allow doctors to save the part of the body where the
cancer started.
PURPOSE: This phase II trial is studying the side effects and how well bortezomib works when
given together with temozolomide and regional radiation therapy in treating patients with
newly diagnosed glioblastoma multiforme or gliosarcoma.
Status | Completed |
Enrollment | 24 |
Est. completion date | April 20, 2018 |
Est. primary completion date | March 29, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Must be >- 18 years old, with a life expectancy > 8 weeks - Histologically confirmed intracranial glioblastoma multiforme (GBM) or gliosarcoma - Must submit an unstained paraffin block or slides from surgical procedure - Patients without prior treatment and with prior diagnosis of lower-grade gliomas that have been upgraded to GBM after repeated resection allowed - At least 21 days since cranial MRI or contrast CT scan OR = 96 hours since cranial MRI or contrast CT scan for patients who underwent surgical resection - Measurable or assessable disease - Voluntary written informed consent obtained before performance of any study related procedure not part of normal medical care. - Karnofsky performance status > 60% - White Blood Count (WBC) = 3,000/mm^3 - absoulte neutrophil count(ANC) = 1,500/mm^3 - Platelet count = 100,000/mm^3 - Hemoglobin = 10 g/dL (transfusion allowed) - Bilirubin < 2.5 times upper limit of normal (ULN) - serum glutamic-oxaloacetic transaminase (SGOT) < 2.5 times ULN - Creatinine < 1.5 mg/dL - Creatinine clearance = 20 mL/minute - Serum sodium > 130 mmol/L - Negative pregnancy test - Fertile patients must use effective contraception - Patients on Enzyme-Inducing Antiepileptic Drugs (EIAED) must be transitioned to non- EAIED for = 2 weeks - Concurrent full-dose warfarin or its equivalent (e.g., unfractionated and/or low molecular weight heparin) allowed Exclusion Criteria: - peripheral neuropathy = grade 2 - Myocardial infarction within the past 6 months - New York Heart Association (NYHA) class III or IV heart failure - Uncontrolled angina - Severe uncontrolled ventricular arrhythmias - Electrocardiographic evidence of acute ischemia or active conduction system abnormalities - hypersensitivity to bortezomib, boron, or mannitol - serious medical or psychiatric illness that would interfere with study participation including, but not limited to, any of the following: - Ongoing or active infection requiring IV antibiotics - Psychiatric illness and/or social situations that would limit compliance with study requirements - Disorders associated with a significant immunocompromised state (e.g., HIV, systemic lupus erythematosus) - history of stroke within the past 6 months - other malignancy within the past 3 years except completely resected basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy (i.e., cervical cancer), or low-risk prostate cancer after curative therapy - significant medical illness that, in the investigator's opinion, cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy - disease that will obscure toxicity or dangerously alter drug metabolism - viral hepatitis (HBV surface antigen positive) or active hepatitis C infection - Prior or concurrent corticosteroids, automated external defibrillator, analgesics, and other drugs to treat symptoms or prevent complications allowed - concurrent investigational drugs that must be stopped at least 4 months prior to therapy. - prior radiotherapy to the brain - prior cytotoxic or noncytotoxic drug therapy or experimental drug therapy (including chemotherapy, hormonal therapy, or immunotherapy) directed against the brain tumor - prior polifeprosan 20 with carmustine implant (Gliadel wafer) - concurrent stereotactic radiosurgery or brachytherapy - concurrent sargramostim - concurrent inducers of CYP450 3A4 (e.g., enzyme-inducing anti-epileptic drugs [EIAED]) |
Country | Name | City | State |
---|---|---|---|
United States | University of California Los Angeles | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Jonsson Comprehensive Cancer Center | Millennium Pharmaceuticals, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Survival | Estimate the overall survival in subjects with newly-diagnosed glioblastoma (GBM) treated with bortezomib/temozolomide/radiation followed by bortezomib/temozolomide for 24 cycles until progression is detected or for up to 24 cycles (~2 years). | 2 years | |
Secondary | Toxicity Assessed According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3. | 2 years | ||
Secondary | Time to Progression | Median time to tumor progression. Because many newly-diagnosed patients are likely not to have evaluable disease due to gross total resections. A 7-point scale was used to guide Magnetic resonance imaging (MRI) assessment to determine progression in this study. A -2 or -3 assessment will be taken as progression. The 7-point scale is listed below. complete resolution of tumor: 3 tumor definitely smaller: 2 tumor probably smaller: 1 tumor unchanged: 0 tumor probably worse: -1 tumor definitely worse: -2 new lesion: -3 |
From the completion of radiation treatment to tumor progression | |
Secondary | Survival at 1 Year | Overall Survival at 12 months from completion of radiation treatment | 1 year | |
Secondary | Tumor Progression as Assessed by Magnetic Resonance Imaging (MRI) and Neurologic Exam | MRI will be done 2 weeks after completion of radiation and then every 8 weeks. Neurologic exam to be performed every 2 weeks during radiation therapy, then every every 4 weeks after radiation is completed. | at 6, 12, 18 and 24 months from completion of radiation treatment. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00006080 -
Fenretinide in Treating Patients With Recurrent Malignant Glioma
|
Phase 2 | |
Recruiting |
NCT00887146 -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
|
Phase 3 | |
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Completed |
NCT00621686 -
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00227032 -
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
|
Phase 1 | |
Terminated |
NCT00243022 -
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
|
Phase 2 | |
Active, not recruiting |
NCT00087815 -
Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
|
N/A | |
Active, not recruiting |
NCT00278278 -
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
|
Phase 3 | |
Completed |
NCT00416819 -
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
N/A | |
Completed |
NCT00052286 -
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
|
N/A | |
Completed |
NCT00006093 -
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT00004129 -
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00003417 -
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00003484 -
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
|
Phase 1 | |
Completed |
NCT00003464 -
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00003020 -
LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
|
Phase 1 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 |